Nebenwirkungen · Xiliarx
Xiliarx 50 mg tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-210549 · Präparat HOS-154539
Hypoglycaemia Hypoglycaemia was uncommon when vildagliptin (0.4%) was used as monotherapy in comparative controlled monotherapy studies with an active comparator or placebo (0.2%). No severe or serious events of hypoglycaemia were reported. When used as add-on to metformin, hypoglycaemia occurred in 1% of vildagliptin-treated patients and in 0.4% of placebo-treated patients. When pioglitazone was added, hypoglycaemia occurred in 0.6% of vildagliptin-treated patients and in 1.9% of placebo-treated patients. When sulphonylurea was added, hypoglycaemia occurred in 1.2% of vildagliptin treated patients and in 0.6% of placebo-treated patients. When sulphonylurea and metformin were added, hypoglycaemia occurred in 5.1% of vildagliptin treated patients and in 1.9% of placebo treated patients. In patients taking vildagliptin in combination with insulin, the incidence of hypoglycaemia was 14% for vildagliptin and 16% for placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T16:30:00Z · SHA-256 c3c779825defe3cdfa205addcc4b8b8a94be37db71677d7ad8fe56f9ecb64ea0 · Passage 0706f91cf3a16bf1239b7ea8a89e6ffdb2039c8b056dfc9320203d3f89e12218 · Zeichen 5791–6725 im Abschnitt